Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant epirubicin + ifosfamide in high-risk superficial soft tissue sarcomas (phase II)
2006-001425-25Phase 2Terminated
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Apr 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epirubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Disease-free survival. Started Apr 2006; status: terminated.
02
Drugs
epirubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2006-001425-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001425-25.